Home › Trials › NCT04637763

CRISPR-edited CAR-T cell therapy for relapsed B cell lymphoma

A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Phase 1 Interventional Caribou Biosciences, Inc. · NCT04637763

This study is testing a new CRISPR-edited CAR-T cell therapy to see if it can help adults with relapsed B cell lymphoma feel better.

Quick facts

PhasePhase 1
Study typeInterventional
Enrollment72 (estimated)
Ages18 Years and up
SexAll
SponsorCaribou Biosciences, Inc. Industry-sponsored
Drugs / interventionscyclophosphamide, fludarabine
Locations38 sites (Birmingham, Alabama and 37 other locations)
Trial IDNCT04637763 on ClinicalTrials.gov

What this trial studies

This clinical trial evaluates the safety and emerging efficacy of CB-010, a CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy, in adults with relapsed or refractory B cell non-Hodgkin lymphoma. The study is structured in two parts: Part A involves dose escalation using a 3 + 3 design to determine the optimal dose, while Part B focuses on expanding the patient cohort to receive the selected dose. Participants will undergo lymphodepletion with cyclophosphamide and fludarabine prior to receiving the treatment.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with a documented diagnosis of relapsed or refractory non-Hodgkin lymphoma after prior standard treatments.

Not a fit: Patients with prior therapy using anti-CD19 targeting agents or those with active CNS lymphoma may not benefit from this study.

Why it matters

Potential benefit: If successful, this therapy could provide a novel treatment option for patients with difficult-to-treat relapsed or refractory B cell non-Hodgkin lymphoma.

How similar studies have performed: Other studies using CAR-T cell therapies have shown promising results, indicating potential success for this novel approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Age greater than or equal to 18 at the time of enrollment
* Documented diagnosis of relapsed or refractory non-Hodgkin lymphoma after prior standard of care
* Eastern Cooperative Oncology Group performance status 0 or 1
* Adequate hematologic, renal, liver, cardiac and pulmonary organ function

Exclusion Criteria:

* Prior therapy with an anti-CD19 targeting agent
* Active or chronic graft versus host disease requiring therapy
* Prior allogeneic stem cell transplantation
* Central nervous system (CNS) lymphoma, prior CNS malignancy
* Prior seizure disorder, cerebrovascular ischemia, dementia, cerebellar disease or autoimmune disease with CNS involvement.
* Primary immunodeficiency
* Current or expected need for systemic corticosteroid therapy
* Current thyroid disorder. Hypothyroidism controlled with stable hormone replacement is permitted
* Other malignancy within 2 years of study entry, except curatively treated malignancies or malignancies with low risk of recurrence
* Unwillingness to follow extended safety monitoring

Where this trial is running

Birmingham, Alabama and 37 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Lymphoma, Non-HodgkinRelapsed Non Hodgkin LymphomaRefractory B-Cell Non-Hodgkin LymphomaNon Hodgkin LymphomaLymphomaB Cell LymphomaB Cell Non-Hodgkin's Lymphoma
Last reviewed 2026-06-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.